 Rohit Katial
Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 39 | 2023 | 2143 | 4.300 |
Why?
| | Anti-Asthmatic Agents | 13 | 2023 | 339 | 3.380 |
Why?
| | Aspirin | 11 | 2018 | 334 | 3.010 |
Why?
| | Hypersensitivity | 8 | 2018 | 270 | 2.860 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 142 | 2.500 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 23 | 2.420 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 32 | 2.380 |
Why?
| | Sinusitis | 9 | 2022 | 175 | 2.010 |
Why?
| | Rhinitis | 6 | 2022 | 129 | 1.590 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 301 | 1.560 |
Why?
| | Nitric Oxide | 7 | 2018 | 891 | 1.460 |
Why?
| | Adrenal Cortex Hormones | 11 | 2022 | 517 | 1.350 |
Why?
| | Nasal Polyps | 6 | 2022 | 49 | 1.260 |
Why?
| | Histamine Antagonists | 4 | 2011 | 19 | 1.250 |
Why?
| | Eosinophils | 12 | 2023 | 282 | 1.140 |
Why?
| | Exhalation | 2 | 2018 | 35 | 1.090 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 41 | 1.080 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 113 | 1.040 |
Why?
| | Immunotherapy | 5 | 2017 | 493 | 1.000 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 75 | 0.970 |
Why?
| | Rhinitis, Allergic | 2 | 2014 | 36 | 0.950 |
Why?
| | Antibodies, Monoclonal, Humanized | 10 | 2023 | 665 | 0.810 |
Why?
| | Pancreatitis | 2 | 2012 | 105 | 0.800 |
Why?
| | Breath Tests | 4 | 2007 | 89 | 0.740 |
Why?
| | Biomarkers | 7 | 2018 | 3567 | 0.740 |
Why?
| | Androstadienes | 2 | 2010 | 95 | 0.730 |
Why?
| | Albuterol | 2 | 2010 | 104 | 0.720 |
Why?
| | Humans | 76 | 2023 | 118251 | 0.660 |
Why?
| | Drug Hypersensitivity | 3 | 2016 | 85 | 0.640 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 54 | 0.640 |
Why?
| | Biological Products | 2 | 2018 | 170 | 0.590 |
Why?
| | Biological Therapy | 1 | 2017 | 26 | 0.580 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 22 | 0.560 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 12 | 0.550 |
Why?
| | Allergy and Immunology | 1 | 2016 | 56 | 0.530 |
Why?
| | Antibodies, Monoclonal | 3 | 2018 | 1279 | 0.530 |
Why?
| | Vaccination | 3 | 2012 | 1218 | 0.520 |
Why?
| | Administration, Intranasal | 6 | 2011 | 79 | 0.510 |
Why?
| | Sputum | 3 | 2013 | 291 | 0.500 |
Why?
| | Allergens | 5 | 2016 | 425 | 0.490 |
Why?
| | Practice Guidelines as Topic | 6 | 2017 | 1433 | 0.470 |
Why?
| | Anaphylaxis | 1 | 2016 | 146 | 0.450 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 520 | 0.450 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 95 | 0.420 |
Why?
| | Disease Progression | 5 | 2023 | 2477 | 0.410 |
Why?
| | Eosinophilia | 4 | 2019 | 185 | 0.400 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 25 | 0.370 |
Why?
| | Mast Cells | 2 | 2013 | 115 | 0.350 |
Why?
| | Acetates | 1 | 2010 | 98 | 0.340 |
Why?
| | Vaccines | 2 | 2004 | 380 | 0.340 |
Why?
| | Quinolines | 1 | 2010 | 128 | 0.340 |
Why?
| | Nose | 1 | 2009 | 58 | 0.330 |
Why?
| | Chronic Disease | 7 | 2022 | 1630 | 0.320 |
Why?
| | Laryngismus | 1 | 2008 | 6 | 0.320 |
Why?
| | Leukotriene E4 | 1 | 2008 | 28 | 0.320 |
Why?
| | Double-Blind Method | 6 | 2023 | 1683 | 0.320 |
Why?
| | Vocal Cords | 1 | 2008 | 30 | 0.310 |
Why?
| | Severity of Illness Index | 4 | 2017 | 2659 | 0.300 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 186 | 0.290 |
Why?
| | Adult | 23 | 2022 | 31324 | 0.290 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 64 | 0.290 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 393 | 0.280 |
Why?
| | Middle Aged | 20 | 2019 | 27510 | 0.280 |
Why?
| | Diagnosis, Differential | 4 | 2017 | 1379 | 0.280 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 357 | 0.270 |
Why?
| | Immunity, Cellular | 1 | 2007 | 268 | 0.270 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.270 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 127 | 0.270 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 5 | 0.270 |
Why?
| | Skin Tests | 1 | 2005 | 135 | 0.260 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 3 | 0.260 |
Why?
| | Male | 25 | 2018 | 57474 | 0.260 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 260 | 0.250 |
Why?
| | Anesthetics, Local | 1 | 2005 | 85 | 0.250 |
Why?
| | Syphilis | 1 | 2004 | 25 | 0.250 |
Why?
| | Analgesia | 1 | 2005 | 81 | 0.250 |
Why?
| | Female | 26 | 2022 | 61261 | 0.250 |
Why?
| | Serum Sickness | 1 | 2004 | 7 | 0.250 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 68 | 0.250 |
Why?
| | Bioterrorism | 1 | 2004 | 19 | 0.240 |
Why?
| | Bupropion | 1 | 2004 | 38 | 0.240 |
Why?
| | Exanthema | 1 | 2004 | 77 | 0.240 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 53 | 0.240 |
Why?
| | Administration, Inhalation | 3 | 2016 | 652 | 0.230 |
Why?
| | Cockroaches | 1 | 2003 | 23 | 0.230 |
Why?
| | Research Design | 1 | 2009 | 961 | 0.230 |
Why?
| | Signal Transduction | 2 | 2016 | 4688 | 0.230 |
Why?
| | Recurrence | 2 | 2017 | 971 | 0.230 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.220 |
Why?
| | Alternaria | 1 | 2002 | 7 | 0.220 |
Why?
| | Treatment Outcome | 9 | 2018 | 9319 | 0.220 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 13 | 0.210 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 19 | 0.210 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 78 | 0.210 |
Why?
| | Poaceae | 1 | 2002 | 70 | 0.210 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 964 | 0.210 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 49 | 0.200 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 69 | 0.200 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 58 | 0.200 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 125 | 0.200 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 116 | 0.200 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 30 | 0.200 |
Why?
| | Young Adult | 9 | 2019 | 10731 | 0.200 |
Why?
| | United States | 5 | 2018 | 12488 | 0.190 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 12 | 0.190 |
Why?
| | Glycoproteins | 1 | 2002 | 317 | 0.190 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 251 | 0.180 |
Why?
| | Respiratory Tract Infections | 1 | 2004 | 329 | 0.180 |
Why?
| | Algorithms | 4 | 2020 | 1522 | 0.180 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.180 |
Why?
| | Adolescent | 10 | 2019 | 18364 | 0.180 |
Why?
| | Drug Combinations | 2 | 2010 | 291 | 0.170 |
Why?
| | Child | 8 | 2019 | 19033 | 0.170 |
Why?
| | Histamine | 2 | 2011 | 65 | 0.170 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 68 | 0.160 |
Why?
| | Cytokines | 2 | 2016 | 1880 | 0.160 |
Why?
| | Bacterial Capsules | 2 | 2012 | 32 | 0.160 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 32 | 0.160 |
Why?
| | Aged | 6 | 2019 | 19594 | 0.160 |
Why?
| | Primary Health Care | 1 | 2008 | 1539 | 0.150 |
Why?
| | Immunoglobulin E | 3 | 2017 | 366 | 0.150 |
Why?
| | Aging | 1 | 2007 | 1675 | 0.150 |
Why?
| | Reference Values | 3 | 2007 | 770 | 0.150 |
Why?
| | Benzamides | 1 | 2018 | 176 | 0.150 |
Why?
| | Pyrroles | 1 | 2018 | 188 | 0.150 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 355 | 0.150 |
Why?
| | Quality of Life | 3 | 2014 | 2355 | 0.150 |
Why?
| | Leukotrienes | 1 | 2016 | 33 | 0.140 |
Why?
| | Allergists | 1 | 2016 | 19 | 0.140 |
Why?
| | Interleukin-4 | 3 | 2013 | 216 | 0.140 |
Why?
| | Venoms | 1 | 2016 | 33 | 0.140 |
Why?
| | Canada | 1 | 2017 | 338 | 0.140 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 39 | 0.130 |
Why?
| | Insecta | 1 | 2016 | 68 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 466 | 0.130 |
Why?
| | Drugs, Generic | 1 | 2015 | 18 | 0.130 |
Why?
| | Lung | 1 | 2007 | 3623 | 0.130 |
Why?
| | Epinephrine | 1 | 2016 | 166 | 0.130 |
Why?
| | Animals | 7 | 2017 | 33152 | 0.120 |
Why?
| | Phosphorylation | 2 | 2016 | 1622 | 0.120 |
Why?
| | Drug Therapy, Combination | 2 | 2023 | 964 | 0.120 |
Why?
| | Basophils | 2 | 2013 | 66 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1770 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2015 | 261 | 0.110 |
Why?
| | Rabies Vaccines | 1 | 2012 | 1 | 0.110 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 4 | 0.110 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.110 |
Why?
| | Drug Resistance | 1 | 2013 | 167 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 168 | 0.110 |
Why?
| | Olfaction Disorders | 1 | 2013 | 47 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 690 | 0.110 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 29 | 0.110 |
Why?
| | Cost of Illness | 1 | 2014 | 255 | 0.100 |
Why?
| | Receptors, Histamine | 1 | 2011 | 5 | 0.100 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 25 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2012 | 117 | 0.100 |
Why?
| | Interleukins | 1 | 2013 | 242 | 0.100 |
Why?
| | History, 19th Century | 1 | 2011 | 61 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 252 | 0.100 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 42 | 0.100 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 140 | 0.100 |
Why?
| | Health Surveys | 2 | 2012 | 453 | 0.100 |
Why?
| | Fluticasone | 1 | 2010 | 87 | 0.100 |
Why?
| | Phenotype | 2 | 2017 | 2937 | 0.090 |
Why?
| | History, 20th Century | 1 | 2011 | 281 | 0.090 |
Why?
| | Cyclopropanes | 1 | 2010 | 80 | 0.090 |
Why?
| | Receptors, IgG | 1 | 2009 | 67 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2022 | 12929 | 0.090 |
Why?
| | Congresses as Topic | 1 | 2011 | 202 | 0.090 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 7 | 0.090 |
Why?
| | Clinical Competence | 1 | 2016 | 950 | 0.090 |
Why?
| | Sulfides | 1 | 2010 | 96 | 0.090 |
Why?
| | Medication Adherence | 1 | 2014 | 554 | 0.090 |
Why?
| | Chemokines, CC | 1 | 2009 | 30 | 0.090 |
Why?
| | Administration, Oral | 1 | 2011 | 753 | 0.080 |
Why?
| | Bone Marrow | 2 | 2013 | 252 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 70 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 174 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2016 | 3156 | 0.080 |
Why?
| | Interleukin-13 | 1 | 2009 | 135 | 0.080 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 25 | 0.080 |
Why?
| | Adenosine | 1 | 2009 | 211 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2018 | 5230 | 0.080 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2009 | 328 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 979 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 650 | 0.070 |
Why?
| | Health Status | 1 | 2012 | 723 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 461 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 523 | 0.070 |
Why?
| | Flushing | 1 | 2005 | 1 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2009 | 785 | 0.070 |
Why?
| | Administration, Topical | 1 | 2005 | 141 | 0.070 |
Why?
| | Infant | 1 | 2018 | 8254 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 933 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3435 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 33 | 0.060 |
Why?
| | Biomedical Research | 1 | 2011 | 600 | 0.060 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 3 | 0.060 |
Why?
| | Child, Preschool | 1 | 2018 | 9448 | 0.060 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 3 | 0.060 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.060 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 23 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1048 | 0.060 |
Why?
| | Francisella tularensis | 1 | 2004 | 19 | 0.060 |
Why?
| | Placebos | 2 | 2018 | 202 | 0.060 |
Why?
| | Diarrhea | 1 | 2005 | 180 | 0.060 |
Why?
| | Yersinia pestis | 1 | 2004 | 34 | 0.060 |
Why?
| | Headache | 1 | 2004 | 128 | 0.060 |
Why?
| | Insect Control | 1 | 2003 | 11 | 0.060 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 60 | 0.060 |
Why?
| | Classification | 1 | 2003 | 23 | 0.060 |
Why?
| | Food Contamination | 1 | 2003 | 45 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 207 | 0.060 |
Why?
| | Comorbidity | 2 | 2018 | 1516 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2008 | 644 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 56 | 0.060 |
Why?
| | Pain Measurement | 1 | 2005 | 468 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2004 | 89 | 0.060 |
Why?
| | Disaster Planning | 1 | 2004 | 76 | 0.060 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 15 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 67 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 32 | 0.050 |
Why?
| | Consumer Product Safety | 1 | 2002 | 31 | 0.050 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 11 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2013 | 6541 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 36 | 0.050 |
Why?
| | Drug Tolerance | 1 | 2002 | 78 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 124 | 0.050 |
Why?
| | Plant Extracts | 1 | 2002 | 164 | 0.050 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 367 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 817 | 0.050 |
Why?
| | Time Factors | 1 | 2010 | 6368 | 0.050 |
Why?
| | Neutrophils | 2 | 2017 | 1142 | 0.050 |
Why?
| | Inflammation | 1 | 2010 | 2545 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5671 | 0.040 |
Why?
| | Gastroesophageal Reflux | 1 | 2002 | 248 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 1130 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 447 | 0.040 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 15 | 0.040 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 7 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2433 | 0.040 |
Why?
| | Methacholine Chloride | 1 | 2018 | 48 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2018 | 46 | 0.040 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 8 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 963 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 526 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4574 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 135 | 0.040 |
Why?
| | Prognosis | 1 | 2005 | 3424 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4684 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 683 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 456 | 0.040 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 144 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2015 | 18 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 27 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1514 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1078 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2435 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 2015 | 80 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 698 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 8958 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 152 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 406 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 347 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 5 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 19 | 0.030 |
Why?
| | Equipment Design | 1 | 2015 | 518 | 0.030 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 59 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2013 | 117 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 748 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 303 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 566 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 333 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2016 | 735 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2011 | 82 | 0.030 |
Why?
| | Efficiency | 1 | 2012 | 88 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 6443 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 97 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 4 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 48 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 139 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 410 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 315 | 0.020 |
Why?
| | Cats | 1 | 2009 | 204 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 172 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 269 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2837 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 238 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 364 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 494 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 552 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 862 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1288 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 685 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4044 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1937 | 0.020 |
Why?
| | ROC Curve | 1 | 2005 | 470 | 0.020 |
Why?
| | Brain | 1 | 2016 | 2481 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4887 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2461 | 0.010 |
Why?
| | Mice | 1 | 2013 | 15446 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2005 | 4521 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|